Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Optimised Cardio-Renal Care for CKD and heart disease

Official title: Optimised Multidisciplinary Cardiovascular and Renal Protection in Patients With Chronic Kidney Disease and Cardiovascular Disease: Effects on Diastolic Function, Cardiovascular and Renal Outcomes

Run by Odense University Hospital · NCT07835828 · Data updated 2026-11-12

This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment500 (estimated)
SponsorOdense University Hospital
Academic / other
Locations1 site (Svendborg)
StatusRecruiting
StartedOctober 1, 2026
Main results expectedOctober 1, 2038
Study endsOctober 1, 2038
Registry record updatedOctober 15, 2026
Trial IDNCT07835828 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with both chronic kidney disease and established cardiovascular disease who can provide informed consent and meet specific kidney function and proteinuria criteria.

Probably not a fit

Patients with HFpEF but no CKD progression, or those unlikely to benefit from multidisciplinary cardio-renal optimization, may see limited improvement.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study examines a multidisciplinary Cardio-Renal Clinic designed to care for patients with both chronic kidney disease and cardiovascular disease, including HFpEF. Participants undergo a structured, guideline-based treatment plan and comprehensive baseline assessments, followed by long-term follow-up to compare outcomes with usual care. Primary questions focus on improvements in heart and kidney function, quality of life, symptoms, and physical ability after one year, with longer-term effects on mortality and major cardiovascular or renal events assessed over five years. The study leverages existing evidence for SGLT2 inhibitors and mineralocorticoid receptor antagonists while addressing gaps in real-world guideline implementation. Eligible participants are adults with CKD and established cardiovascular disease, excluding those with HF with reduced ejection fraction, diabetes, dialysis, kidney transplant, or limited life expectancy.

Why it matters

Potential benefit: If successful, patients could experience better heart and kidney health, fewer symptoms, and improved overall well-being through a coordinated, guideline-based care approach.

How similar studies have gone: Previous pilots and related trials suggest structured cardio-renal care can improve process measures and outcomes, though results vary by setting and population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 18 years old
* Capable of giving written informed consent
* Established chronic kidney disease, and at least two measurements of: 1) eGFR \<45 and \>15 mL/min/1.73 m², and/or 2) UACR \>200 mg/g, or 3) eGFR \<60 mL/min/1.73 m² and UACR \>30 mg/g.
* Established cardiovascular disease, including prior acute coronary syndrome, chronic coronary syndrome, objective evidence of myocardial ischaemia, non-coronary atherosclerotic cardiovascular diase (stroke or peripheral arterial disease), heart failure with preserved ejection fraction, atrial fibrillation and/or flutter, clinically significant valvular disease, or hypertension treated with three or more antihypertensive drugs.

Exclusion Criteria:

* Established heart failure with reduced ejection fraction.
* Diabetes type I or II
* Patients receiving chronic dialysis or having of kidney transplant.
* Expected life expectancy \<5 years.
* Inability to understand the study procedures, comply with study requirements, or presence of any condition that, in the opinion of the research staff, may interfere with the patient's ability to participate in or complete the study.
* Participation in another clinical trial with an investigational product or device that could interfere with the primary and/or secondary endpoints of this study.

Where it's running

  • Cardiovascular Research Unit, Odense University Hospital Svendborg
    Svendborg, Denmark
    Recruiting

Study contacts

  • Principal investigator: Søren Auscher, MD, PhD, Associated Professor — Odense University Hospital
  • Study coordinator: Eline Panadevo, MD
  • Email: eline.panadevo@rsyd.dk
  • Phone: +45 63 20 24 02

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.